Vol.65 No.6 November 2017

In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus 2012 through 2015 in Japan

Makoto Miyazaki¹⁾, Hidetoshi Ikeda¹⁾, Toshinori Kurokawa²⁾, Katsuhiko Tamura²⁾, Takayuki Kondo²⁾, Akira Kawai²⁾ and Mitsuyoshi Hara¹⁾

¹⁾Pharmacovigilance Area, MSD K.K., KITANOMARU SQUARE, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, Japan
²⁾Medical Affairs Japan, MSD K.K.

Abstract

The in vitro activity of daptomycin (DAP) along with comparator drugs, vancomycin, teicoplanin, linezolid, and arbekacin, against methicillin-resistant Staphylococcus aureus (MRSA) recovered from blood (n = 300) and skin infection sites (n = 600) from patients in Japan between April 2012 and April 2015 was investigated. The antimicrobial susceptibility of MRSA was tested with the broth microdilution method according to the Clinical and Laboratory Standards Institution (CLSI) M7-A8 for each annual period and the interpretative criteria of CLSI M100-S21 were used for the MIC clinical breakpoints.
The minimum inhibitory concentration of DAP for 90% of isolates (MIC₉₀) against MRSA was 0.5 μg/mL during each annual period (2012, 2013 and 2014) and all isolates from blood and skin infection sites were susceptible to DAP. The geometric mean of MICs during the annual periods of 2012, 2013 and 2014 were 0.48, 0.37, and 0.39 μg/mL for isolates from blood and 0.40, 0.34, and 0.42 μg/mL for isolates from skin infection sites, respectively, and the variation of the geometric mean of MICs for each year were also within 2-fold. All isolates were also susceptible to the comparator drugs.
These results suggested that the in vitro activity of DAP against MRSA isolates from blood and skin infection sites remained relatively unchanged during 2012-2015 in Japan.

Key word

daptomycin, vancomycin, MRSA, surveillance, antimicrobial susceptibility

Received

December 19, 2016

Accepted

September 4, 2017

Jpn. J. Chemother. 65 (6): 821-824, 2017